Inferra AI / Company / ALMR
Alamar Biosciences, Inc.
ALMR · Health Care
Last earnings Aug 10, 2026
Key results
Revenuequarter
$26.0 million
Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
First Quarter 2026 Financial Results Revenue was $26.0 million for the first quarter of 2026, a 99% increase from $13.1 million for the corresponding prior-year period.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
Instrument revenuequarter
78%
Instrument revenue grew 78% to $7.4 million, from $4.1 million for the corresponding prior-year period, driven primarily by an increase in instrument placements.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
Consumable revenuequarter
178%
Consumable revenue grew 178% to $14.0 million, from $5.0 million for the corresponding prior-year period, driven primarily by pull-through tied to the larger instrument installed base as well as by a slight increase in the average selling price of our consumables.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
Services and other revenue grew 20% to $4.7 million, from $3.9 million for the corresponding prior-year period.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
Gross marginquarter
56%
Gross margin was 56% for the first quarter of 2026, as compared to 49% for the corresponding prior-year period.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
AI analysis
Q1 2026 · reported May 8, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
GAAP gross margin
Percent of revenue, as stated
EX-99 · May 8, 2026 Margin values as stated in the release.
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $26.0 million | — | — |
| Instrument revenue | 78% | — | — |
| Consumable revenue | 178% | — | — |
| Gross margin | 56% | — | 49% |
Guidance · company-stated
No guidance located in the held release
“Providing full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint of the range as compared to 2025 We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year, said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences.”
Margin
Capital allocation
As of June 30, 2026 and December 31, 2025 , 311,822 and 35,629 shares of common stock granted pursuant to the early exercise of options were outstanding and subject to the Company s repurchase right.
Company-stated claims
Historical · grew 147% · revenue
“Consumable revenue grew 147% to $15.5 million, from $6.3 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels.”
EX-99 · Aug 10, 2026Event summary
Alamar Biosciences Reports First Quarter 2026 Financial Results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
As of June 30, 2026 and December 31, 2025 , 311,822 and 35,629 shares of common stock granted pursuant to the early exercise of options were outstanding and subject to the Company s repurchase right.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Strategy & priorities
The year-over-year increase in operating expenses was primarily related to increased personnel costs, increased costs related to expansion of our product offerings, and increased professional costs for legal and accounting services.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
All statements, other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
If we do not successfully develop and introduce new assays for our ARGO HT instrument and new versions of our ARGO HT instrument, we may not generate new sources of revenue and may not be able to successfully implement our growth strategy.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The segment focuses on developing a highly sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Risks & headwinds
Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
SEC original ↗Alamar Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 8, 2026
These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Legal Proceedings 37 Item 1A.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
We have been, and in the future may be, involved in legal proceedings, regulatory inquiries and other legal matters, which may have an adverse effect on our business, financial condition, results of operations and prospects.
SEC original ↗Alamar Biosciences, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
7 documentsEarnings releases
2 documentsPresentations
0 documentsNo presentations for Alamar Biosciences, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Alamar Biosciences, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.